▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #306 by analyst upside · 2026-08-12
CMPX
Compass Therapeutics, Inc.
Healthcare · Market Cap $396M · P/E 0x
ANALYST PRICE TARGET
+305.3%
implied upside to consensus target
Current Price $2.2
Consensus Target $8.92
Bull Target $24.0
Bear Target $5.0
Analysts Covering 12
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
10
Hold
1
Sell
0
52-Week Low $1.61
52-Week High $6.88
YTD Return -57.4%
FUNDAMENTALS
Market Cap $396M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.39
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.61
52-Week High $6.88
Current Price $2.2
Bear Target $5.0
Bull Target $24.0
● Now $2.2 ● Target $8.92
TRADING DATA
Avg Volume 3.6M
YTD Return -57.4%
Analyst Count 12
Consensus Buy
Upside to Target +305.3%
Last Updated 2026-08-12

ANALYST SUMMARY

Compass Therapeutics, Inc. (CMPX) is currently trading at $2.2 with a Wall Street consensus price target of $8.92, implying potential upside of 305.3% over the next 12 months. 12 analysts currently cover CMPX, with a consensus rating of Buy - 92% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $24.0, while the most cautious has a target of $5.0.

CMPX operates in the Healthcare sector with a market capitalisation of $396M. The stock is down 57.4% year-to-date and is currently trading near the lower end of its 52-week range of $1.61 – $6.88.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

NAGE +292.3%
Niagen Bioscience, Inc.
$244M · P/E 16.2x · Buy
PALI +377.7%
Palisade Bio, Inc.
$373M · P/E 17.8x · Buy
PLX +352.7%
Protalix BioTherapeutics, Inc.
$196M · P/E 12.8x · Buy
SABS +209.5%
SAB Biotherapeutics, Inc.
$342M · P/E 15.7x · Buy
AGEN +185.5%
Agenus Inc.
$307M · P/E 2.3x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CMPX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity - Reiterated
Buy → Buy 2026-04-28 Building track record
Citizens reit
Market Outperform → Market Outperform 2026-04-28 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-04-27 31% win rate (48 calls)
D. Boral Capital - Reiterated
Buy → Buy 2026-04-27 32% win rate (25 calls)
Guggenheim reit
Buy → Buy 2026-03-24 62% win rate (8 calls)
D. Boral Capital - Reiterated
Buy → Buy 2026-01-06 32% win rate (25 calls)
William Blair ● Initiated
Outperform 2026-01-05 44% win rate (9 calls)
Cantor Fitzgerald ● Initiated
Overweight 2025-12-03 40% win rate (10 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
42
out of 100
Coverage depth
20/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →